Sci. Signal., 24 September 2013
Science Signaling Podcast: 24 September 2013
Martin L. Miller1, Chris Sander1, and Annalisa M. VanHook2
1 Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Abstract: This Podcast features an interview with Martin Miller and Chris Sander, authors of a Research Article that appears in the 24 September 2013 issue of Science Signaling. Although anticancer drug treatment may initially kill tumor cells, the cells often acquire resistance to the drug and resume proliferation. One way to reduce the likelihood of resistance and increase drug efficacy is to simultaneously treat tumors with two or more drugs that target different cellular proteins. Miller et al. found that simultaneous inhibition of CDK4 (cyclin-dependent kinase 4) and IGF1R (insulin-like growth factor 1 receptor) synergistically inhibited proliferation of two patient-derived dedifferentiated liposarcoma cell lines. Liposarcomas are tumors that develop from fat cells, and dedifferentiated liposarcoma is a subtype that is particularly aggressive and difficult to treat. The authors then used network modeling to identify the signaling pathways mediating this synergistic effect.
Citation: M. L. Miller, C. Sander, A. M. VanHook, Science Signaling Podcast: 24 September 2013. Sci. Signal. 6, pc25 (2013).
The editors suggest the following Related Resources on Science sites:
In Science Signaling
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882